SCHEMBL10189378

SCHEMBL10189378

COc1ccc(-c2csnc2-c2cc(C)c(OC)c(OC)c2)cc1NC(=O)C(C)N

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.38
XIAP P98170 1/20 0.37
PDE4A P27815 2/20 0.36
PDE4B Q07343 2/20 0.36
PDE4C Q08493 2/20 0.36
PDE4D Q08499 2/20 0.36
RXFP1 Q9HBX9 1/20 0.35
MAPT P10636 2/20 0.35
CIT O14578 1/20 0.35
ADORA3 P0DMS8 1/20 0.34
ADORA2B P29275 1/20 0.34
AAK1 Q2M2I8 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
MAPK1 P28482 1/20 0.34
HSD17B10 Q99714 1/20 0.34
PRKCI P41743 1/20 0.34
PRKCZ Q05513 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL617444 0.94 LMNA (0.40) LMNAPDE4APDE4BPDE4CPDE4D
Hydrochloric Acid SCHEMBL616095 0.93 LMNA (0.40) LMNAPDE4APDE4BPDE4CPDE4D
SCHEMBL10189396 0.93 LMNA (0.37) LMNARXFP1MAPTCITADORA3
SCHEMBL10189395 0.93 LMNA (0.37) LMNARXFP1MAPTCITADORA3
SCHEMBL10189390 0.93 LMNA (0.39) LMNARXFP1MAPTCITADORA3
SCHEMBL10189391 0.93 LMNA (0.39) LMNARXFP1MAPTCITADORA3
SCHEMBL10189393 0.90 AAK1 (0.39) LMNARXFP1MAPTCITAAK1
SCHEMBL10189394 0.90 AAK1 (0.39) LMNARXFP1MAPTCITAAK1
SCHEMBL10189408 0.89 ALDH1A1 (0.39) LMNARXFP1MAPTAAK1ALDH1A1
SCHEMBL10189406 0.89 ALDH1A1 (0.39) LMNARXFP1MAPTAAK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SUN LIJUN (US) 2013-08-08 US disclosed
US-8399435-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-03-19 US disclosed
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 LMNA 2274/4885XIAP 1483/4885PDE4A 2046/4885
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 LMNA 2274/4885XIAP 1483/4885PDE4A 2046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.